Rheumatology Advance Access published online on August 27, 2006
Rheumatology, doi:10.1093/rheumatology/kel296
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Johns Hopkins University, Baltimore, MD, USA
* To whom correspondence should be addressed. Objective. To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies. Methods. Two multi-centre, 26-week, double-blind, placebo-controlled, non-inferiority studies were conducted, enrolling patients who were prior non-steroidal anti-inflammatory drug (NSAID) or acetaminophen users. There were 599 patients in study 1 and 608 patients in study 2 randomized 4:4:1:1 to etoricoxib 30 mg qd, celecoxib 200 mg qd or one of two placebo groups for 12 weeks. After 12 weeks, placebo patients were evenly distributed to etoricoxib or celecoxib based on their initial enrollment randomization schedule. The primary hypothesis was that etoricoxib 30 mg would be at least as effective as celecoxib 200 mg for the time-weighted average change from baseline over 12 weeks for Western Ontario and McMaster (WOMAC) Pain Subscale, WOMAC Physical Function Subscale and Patient Global Assessment of Disease Status. Active treatments were also assessed over the full 26 weeks. Adverse experiences were collected for safety assessment. Results. In both studies, etoricoxib was non-inferior to celecoxib for all three efficacy outcomes over 12 and 26 weeks; both were superior to placebo (P < 0.001) for all three outcomes in each study over 12 weeks. The safety and tolerability of etoricoxib 30 mg qd and celecoxib 200 mg qd were similar over 12 and 26 weeks. Conclusions. Etoricoxib 30 mg qd was at least as effective as celecoxib 200 mg qd and had similar safety in the treatment of knee and hip OA; both were superior to placebo. ClinicalTrials.gov Identifiers: NCT00092768; NCT00092791
Received January 19, 2006
Accepted June 9, 2006
Original Papers
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies
C. O. Bingham III 1 *, A. I. Sebba 2, B. R. Rubin 3, G. E. Ruoff 4, J. Kremer 5, S. Bird 6, S. S. Smugar 6, B. J. Fitzgerald 6, K. O’Brien 6, and A. M. Tershakovec 6
2 Arthritis Associates, Palm Harbor, FL, USA
3 University of North Texas, Fort Worth, TX, USA
4 Westside Family Medical Centre, Kalamazoo, MI, USA
5 The Centre for Rheumatology, Albany, NY, USA
6 Merck & Co., Inc., West Point, PA, USA
C. O. Bingham III, E-mail: Clifton.bingham{at}jhmi.edu
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Chilet-Rosell, M. T. Ruiz-Cantero, and J. F. Horga Women's health and gender-based clinical trials on etoricoxib: methodological gender bias J. Public Health Med., September 1, 2009; 31(3): 434 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. O. Bingham III, S. S. Smugar, H. Wang, and A. M. Tershakovec Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo Rheumatology, September 1, 2009; 48(9): 1122 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Ross, K. P. Hill, D. S. Egilman, and H. M. Krumholz Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation JAMA, April 16, 2008; 299(15): 1800 - 1812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. O. Bingham Response to Dr Gotzche and Dr Bjarnason Rheumatology, October 1, 2007; 46(10): 1624 - 1625. [Full Text] [PDF]
|
|
|
|
|
|
P. C. Gotzsche and N. H. Bjarnason COX-2 inhibitor Rheumatology, October 1, 2007; 46(10): 1623 - 1624. [Full Text] [PDF]
|
|